Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by a sustained elevation of the platelet count and a tendency for thrombosis and haemorrhage. Cytogenetic abnormalities are rare in ET, accounting for \<5% of cases. Molecular abnormalities include *JAK2* V617F \[Mendelian Inheritance in Man (MIM) reference 614521\], a mutation found in 50% of ET patients (Kralovics *et al*, [@b5]). In addition, a small fraction of *JAK2* V617F-negative ET patients (about 10%) have activating point mutations in the thrombopoietin receptor gene (*MPL*, MIM 159530) (Kilpivaara & Levine, [@b4]). Other genes were also found to be mutated in ET, such as *TET2, LNK* and *ASXL1,* but at a low frequency. As such, the underlying molecular cause remains to be discovered in a substantial fraction of ET cases.

Recently, Hou *et al* ([@b3]) developed a high-throughput single-cell sequencing method for sequencing the cancer genome with high accuracy at the nucleotide level to facilitate the analysis of tumour evolution in cancers. They applied their method on single cells derived from an ET *JAK2* V617F-negative patient and identified several mutated genes. Based on the type, frequency, *in silico* analysis and score of the detected mutations, eight genes were identified as potential candidate drivers: *SESN2*, *DNAJC17*, *ST13*, *TOP1MT*, *NTRK1*, *ABCB5*, *FRG1*, and *ASNS*. However, their recurrence rate in ET was not determined. As none of these genes have been linked to ET before, our aim was to screen a large cohort of ET patients to verify the recurrence rate of these mutations.

Peripheral blood (*n* = 31) or bone marrow (*n* = 33) was collected from a cohort of 64 patients diagnosed with ET according to the World Health Organization criteria (Vardiman *et al*, [@b7]) and verified to be *JAK2* V617F-negative and *MPL* wild-type by allele-specific polymerase chain reaction (PCR) and Sanger sequencing, respectively. We checked the presence and recurrence of the mutations in *SESN2*, *DNAJC17*, *ST13* and *TOP1MT*, which exhibited the highest scores in the study reported by Hou *et al* ([@b3]), and *NTRK1*, which encodes a tyrosine kinase, in a large cohort of 64 *JAK2* V617F- and *MPL* W515L/K-negative ET patients. PCR primers were designed to amplify the full exonic region encompassing the reported mutations: SESN2 p.P87S*,* TOP1MT p.S479L, ST13 p.Q349\*, NTRK1 p.N323S, DNAJC17 p.A292P (Table [1](#tbl1){ref-type="table"}). The generated amplicons were analysed by Sanger sequence analysis.

###### 

Overview of the investigated genes, exons, and mutations.

  Gene                   Exon   Nucleotide change   AA change                               Amplicon size   Primers
  ---------------------- ------ ------------------- --------------------------------------- --------------- ----------------------
  *SESN2*                3      c.259C\>T           P87S                                    311             TTTGATGAGTGGGGCAGGA
  CAAAGGACAGAACCCACCA                                                                                       
  *TOP1MT*               11     c.1436T\>C          S479L                                   416             GTGCCTGTGTGAGTGGAAG
  CAGGAAAAGGGTCCAGACAG                                                                                      
  *ST13*                 12     c.1045C\>T          Q349[\*](#tf1-1){ref-type="table-fn"}   306             CACTCATCTAAACCCCATT
  TCTAGGTTGCTTTTCCTTC                                                                                       
  *NTRK1*                8      c.878A\>G           N323S                                   667             CCTGTGGGGCTGTGACTTAT
  GCAGGAAGTTGGCTGTAACC                                                                                      
  *DNAJC17*              11     c.874G\>C           A292P                                   333             GAGACTCTTAGAACGCAGCA
  CCCAGCACCTTATACCTAT                                                                                       

cDNA sequence of *SESN2*, *TOP1MT*, *ST13*, *NTRK1*, and *DNAJC17* are available at Refseq nucleic NM_031459.4, NM_052963.2, NM_003932.4, NM_001012331.1, NM_018163.2, respectively, in which nucleotide 1 is the A of the ATG-translation initiation codon.

Indicates a stop codon.

Our sequencing experiments did not reveal any of the mutations reported by Hou *et al* ([@b3]). However, our sequencing covered the exon involved in each gene, detecting two other novel heterozygous mutations. The first mutation was in exon 11 of *DNAJC17* (c.877C\>T, p.R293W), and was predicted to be benign by polyphen 2 (<http://genetics.bwh.harvard.edu/pph2/>) (Adzhubei *et al*, [@b1]). This mutation was also detected in the buccal swab of the patient indicating that it is germline. The second mutation was in exon 11 of *TOP1MT* (c.1400A\>G, p.N467S). It was predicted to be damaging by polyphen 2 and SIFT (<http://sift.bii.a-star.edu.sg/>) and was not present in the buccal swab corroborating it as an acquired mutation. *TOP1MT* is localized on human chromosome 8q24.3. It is highly homologous to the nuclear *TOP1* gene and consists of 14 exons. TOP1MT is a mitochondrial topoisomerase encoded by the genomic DNA. It is a type IB enzyme, which sustains the befitting conformation of DNA during replication, transcription, recombination and repair. In addition to the main form of *TOP1MT* mRNA, two alternatively spliced forms were found, which appeared more frequent in renal cell carcinoma compared to normal adjacent tissue (Zhang *et al*, [@b9]). TOP1MT was found to be overexpressed in haematological cancer cell lines in parallel with MYC overexpression leading to the assumption that MYC expression induces TOP1MT expression (Zoppoli *et al*, [@b10]).

We assessed the effect of the mutation p.N467S on the structure of the protein by implementing *in silico* analysis. Amino acid sequences of wild-type and mutated TOP1MT sequences (Refseq: NP_443195; Uniprot: Q969P6) were supplied to the automated I-TASSER server (<http://zhanglab.ccmb.med.umich.edu/>) (Roy *et al*, 2010). The obtained 3D structures were viewed on DeepView--Swiss-PdbViewer (<http://www.expasy.org/spdbv/>) (Guex & Peitsch, 1997). Models were energy minimized by performing two cycles of steepest descent with 50 steps each and one cycle of conjugate gradient of 200 steps with a minimum ΔE of 0·01 kJ/mol together with a harmonic constraint of 100 kJ/mol. The resulting models were further refined by ModRefiner (<http://zhanglab.ccmb.med.umich.edu/ModRefiner>) in order to obtain the best possible conformation of TOP1MT (Xu & Zhang, [@b8]). The final images were rendered on POV-Ray v3.6 (<http://www.povray.org>). By comparison, the major changes caused by p.N467S mutation were the gain of an α helix and the loss of a β strand (Fig[1](#fig01){ref-type="fig"}A) which are in close proximity to the bound DNA molecule. This suggests that this mutation might affect the interaction of TOP1MT with the DNA molecule (Fig[1](#fig01){ref-type="fig"}B).

![TOP1MT p.N467S leads to a structural change that might affect the interaction of TOP1MT with DNA. In comparison to wild-type (Wt) TOP1MT, the mutated (Mt) TOP1MT gained an α helix (red arrows) and lost a β strand (blue arrows) in addition to other conformational changes (A). The sites of structural change are in close proximity to the DNA molecule when bound to TOP1MT (B). Alignment of TOP1MT (amino acid 445 to 502) from UNIPROT on Jalview for human, mouse, rat, and chimpanzee shows that asparagine (N, in purple) at position 467 is conserved between these organisms (C). Representation of amino acid changes in TOP1MT as a result of missense mutations, collected from the COSMIC database, indicates that p.N467S is a new variant located in close proximity to other reported mutations from other cancers (D).](bjh0165-0734-f1){#fig01}

Moreover, TOP1MT is a highly conserved protein; by aligning TOP1MT from different species on Jalview we could confirm that Asparagine at position 467 is conserved (Fig[1](#fig01){ref-type="fig"}C). Moreover, although this mutation has not been reported before in the catalogue of somatic mutations in cancer (COSMIC), two other mutations were reported in close proximity, c.1384G\>A p.V462M and c.1390A\>G p.I464V in adenocarcinoma and endometrioid carcinoma, respectively (Fig[1](#fig01){ref-type="fig"}D). To check the recurrence of the p.N467S in ET, we screened exon 11 of *TOP1MT* gene in 38 additional *JAK2* V617F-negative *MPL* wild-type ET cases, but did not detect any additional mutant cases.

In summary, in this series of *JAK2* V617F and *MPL* W515K/L negative ET cases, we did not detect any of the mutations that were previously proposed as potential candidate drivers (Hou *et al*, [@b3]). However, a novel mutation in exon 11 of *TOP1MT* was found. This establishes this gene as recurrently mutated in *JAK2* V617F and *MPL* W515K/L negative ET, and suggests that *TOP1MT* mutations are involved, at low frequency, in the pathogenesis of ET. However, its functional consequences remain to be investigated. Given that the candidate mutations, as proposed by Hou *et al* ([@b3]) were predicted to be protein damaging, the possibility remains that other exons of these genes might harbour loss of function mutations. The quest for the full complement of driver mutations in ET therefore remains open.
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Note added in proof
===================

After submission of this paper, two independent groups published that *CALR* mutations are recurrent in *JAK2* V617F and *MPL* W515 K/L negative ET (Klampfl *et al*, [@b1]; Nangalia *et al*, [@b2000]). Our case with the *TOP1MT* mutation discussed here, was indeed found to have a *CALR* exon 9 insertion p.K385fs\*47. The interaction between these mutations remains to be investigated.
